WO2001052824A3 - Verwendung spezieller verbindungen zur prophylaxe und therapie von hepatitis c - Google Patents

Verwendung spezieller verbindungen zur prophylaxe und therapie von hepatitis c Download PDF

Info

Publication number
WO2001052824A3
WO2001052824A3 PCT/EP2001/000390 EP0100390W WO0152824A3 WO 2001052824 A3 WO2001052824 A3 WO 2001052824A3 EP 0100390 W EP0100390 W EP 0100390W WO 0152824 A3 WO0152824 A3 WO 0152824A3
Authority
WO
WIPO (PCT)
Prior art keywords
prophylaxis
hepatitis
treatment
particular compounds
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/000390
Other languages
English (en)
French (fr)
Other versions
WO2001052824A2 (de
Inventor
Lutz Weber
Sven Nerdinger
Michael W Cappi
Dirk Behnke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morphochem GmbH
Original Assignee
Morphochem AG fuer Kombinatorische Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphochem AG fuer Kombinatorische Chemie filed Critical Morphochem AG fuer Kombinatorische Chemie
Priority to AT01909624T priority Critical patent/ATE279182T1/de
Priority to AU37302/01A priority patent/AU3730201A/en
Priority to EP01909624A priority patent/EP1248603B1/de
Priority to US10/181,515 priority patent/US20030153594A1/en
Priority to JP2001552872A priority patent/JP2003520225A/ja
Priority to DE2001504100 priority patent/DE50104100D1/de
Priority to IL15010001A priority patent/IL150100A0/xx
Priority to CA002393694A priority patent/CA2393694A1/en
Publication of WO2001052824A2 publication Critical patent/WO2001052824A2/de
Publication of WO2001052824A3 publication Critical patent/WO2001052824A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)

Abstract

Die vorliegende Erfindung betrifft die Verwendung einer Verbindung der Formel (I), worin U-V-W (R1)-X(R2)-Y-Z die Formel RHN-C=CR1-CR2=C-OH, HO-C=CR1-CR2=C-OH oder O=C-CR1=CR2-C=O aufweist, A ein N-Atom oder die Gruppe CH ist, R ein H-Atom, eine C1-C6-Alkyl- oder eine Benzylgruppe ist, R1 ein H-Atom oder eine Methylgruppe ist, und R2 ein H-Atom oder eine Gruppe der Formel (II) oder (III) ist, zur Therapie oder Prophylaxe von Hepatitis C.
PCT/EP2001/000390 2000-01-17 2001-01-15 Verwendung spezieller verbindungen zur prophylaxe und therapie von hepatitis c Ceased WO2001052824A2 (de)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AT01909624T ATE279182T1 (de) 2000-01-17 2001-01-15 Verwendung spezieller verbindungen zur prophylaxe und therapie von hepatitis c
AU37302/01A AU3730201A (en) 2000-01-17 2001-01-15 Use of particular compounds for prophylaxis and treatment of hepatitis
EP01909624A EP1248603B1 (de) 2000-01-17 2001-01-15 Verwendung spezieller verbindungen zur prophylaxe und therapie von hepatitis c
US10/181,515 US20030153594A1 (en) 2000-01-17 2001-01-15 Use of particular compounds for prophylaxis and treatment of hepatitis c
JP2001552872A JP2003520225A (ja) 2000-01-17 2001-01-15 Ｃ型肝炎の予防及び治療用特殊化合物の使用
DE2001504100 DE50104100D1 (de) 2000-01-17 2001-01-15 Verwendung spezieller verbindungen zur prophylaxe und therapie von hepatitis c
IL15010001A IL150100A0 (en) 2000-01-17 2001-01-15 Pharmaceutical compositions containing fused cyclic compounds
CA002393694A CA2393694A1 (en) 2000-01-17 2001-01-15 Use of particular compounds for prophylaxis and treatment of hepatitis c

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10001729A DE10001729A1 (de) 2000-01-17 2000-01-17 Verwendung spezieller Verbindungen zur Prophylaxe und Therapie von Hepatitis C
DE10001729.0 2000-01-17

Publications (2)

Publication Number Publication Date
WO2001052824A2 WO2001052824A2 (de) 2001-07-26
WO2001052824A3 true WO2001052824A3 (de) 2002-03-07

Family

ID=7627769

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/000390 Ceased WO2001052824A2 (de) 2000-01-17 2001-01-15 Verwendung spezieller verbindungen zur prophylaxe und therapie von hepatitis c

Country Status (8)

Country Link
EP (1) EP1248603B1 (de)
JP (1) JP2003520225A (de)
AT (1) ATE279182T1 (de)
AU (1) AU3730201A (de)
CA (1) CA2393694A1 (de)
DE (2) DE10001729A1 (de)
IL (1) IL150100A0 (de)
WO (1) WO2001052824A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20031011A1 (it) * 2003-05-20 2004-11-21 Vanetta S P A Composti biocidi per il trattamento delle acque.
CA2556437A1 (en) * 2004-02-20 2005-09-09 Robert F. Hofmann Use of targeted oxidative therapeutic formulation in treatment of viral diseases
CA2557634A1 (en) * 2004-03-04 2005-09-15 Takeda Pharmaceutical Company Limited Stable capsule preparation
GB0806794D0 (en) * 2008-04-15 2008-05-14 Ludwig Inst Cancer Res Therapeutic compounds

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2502008A1 (fr) * 1981-03-19 1982-09-24 Chekroun Mehir Composition pharmaceutique a base de gomme ammoniaque utile dans le traitement de diverses maladies et application de cette composition au traitement de tumeurs malignes
EP0173262A2 (de) * 1984-08-24 1986-03-05 Carnivora-Deutschland GmbH Verwendung von 1,4-Naphthochinon-Derivaten in niedrigen Konzentrationen zur Immunstimulation
EP0288962A2 (de) * 1987-04-28 1988-11-02 Fujisawa Pharmaceutical Co., Ltd. Arylaralkylether, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung
WO1994002125A1 (en) * 1992-07-24 1994-02-03 The Regents Of The University Of California Method for preventing and treating a viral condition by inhibiting membrane fusion
WO1998019670A2 (en) * 1996-11-01 1998-05-14 Thomas Najarian Combination therapy of hepatitis c infections

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2502008A1 (fr) * 1981-03-19 1982-09-24 Chekroun Mehir Composition pharmaceutique a base de gomme ammoniaque utile dans le traitement de diverses maladies et application de cette composition au traitement de tumeurs malignes
EP0173262A2 (de) * 1984-08-24 1986-03-05 Carnivora-Deutschland GmbH Verwendung von 1,4-Naphthochinon-Derivaten in niedrigen Konzentrationen zur Immunstimulation
EP0288962A2 (de) * 1987-04-28 1988-11-02 Fujisawa Pharmaceutical Co., Ltd. Arylaralkylether, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung
WO1994002125A1 (en) * 1992-07-24 1994-02-03 The Regents Of The University Of California Method for preventing and treating a viral condition by inhibiting membrane fusion
WO1998019670A2 (en) * 1996-11-01 1998-05-14 Thomas Najarian Combination therapy of hepatitis c infections

Also Published As

Publication number Publication date
CA2393694A1 (en) 2001-07-26
ATE279182T1 (de) 2004-10-15
DE10001729A1 (de) 2001-07-26
DE50104100D1 (de) 2004-11-18
AU3730201A (en) 2001-07-31
IL150100A0 (en) 2002-12-01
WO2001052824A2 (de) 2001-07-26
EP1248603B1 (de) 2004-10-13
EP1248603A2 (de) 2002-10-16
JP2003520225A (ja) 2003-07-02

Similar Documents

Publication Publication Date Title
WO2002004444A3 (en) Heterocycle carboxamides as antiviral agents
WO2002004422A3 (en) Heterocycle carboxamides as antiviral agents
WO2001019828A3 (en) Kinase inhibitors as therapeutic agents
WO2005061458A3 (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
PL376119A1 (en) Novel piperidine derivatives for use in the treatment of chemokine mediated disease states
DE602004008895D1 (en) Dpp-iv-hemmer
MY138525A (en) Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
WO2003006425A3 (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
WO2004014913A3 (en) Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors
IL161317A0 (en) 4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes
AU7824900A (en) Compounds and methods for inhibiting mrp1
MY117789A (en) Pyrroloquinolones as antiviral agents
WO2004030664A3 (en) New compounds for the inhibition of undesired cell proliferation and use thereof
WO2002016322A3 (en) Process for the preparation of 2-aminoethylpyridines
BG107050A (en) Method for the preparation of citalopram
AU9025601A (en) Cephem compounds and esbl-detecting reagents containing the same
WO2000046210A3 (en) New process for preparing pesticidal intermediates
WO2001052824A3 (de) Verwendung spezieller verbindungen zur prophylaxe und therapie von hepatitis c
EP1393747A4 (de) Mittel zur prävention/behandlung von alzheimer-krankheit
WO2005061496A8 (en) Aminopyridine-derivatives as inductible no-synthase inhibitors
BR0200536A (pt) Compostos de sulfonilpiridazinana úteis como inibidores de aldose reductase
EP2279741A3 (de) Caprolactame und deren Verwendung als entzündungshemmende Mittel
WO2002024690A8 (en) Efficient process for the preparation of a factor xa inhibitor
IL145449A0 (en) Processes for preparing pesticidal intermediates
MY129094A (en) Condensed polycyclic compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2393694

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 150100

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2001909624

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 37302/01

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 552872

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2001909624

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10181515

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2001909624

Country of ref document: EP